BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025
• 2026

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 19
• 20
• 21
• 22
• 23
• 24
• 26
• 27
• 28
• 29
• 30

• 

  Business

  Teva Expected to Fire Up to 1,700 Workers in Israel, U.S.

  News of the layoffs comes hard on the heels of the company’s credit rating having been cut to junk status by Fitch Rating.

  November 27, 2017

   · 

  2 min read

   · 

  Alex Keown
• 

  Drug Development

  Regeneron Abandons Ship as Combo Drug Flunks Phase II Studies

  Regeneron indicated that because of disappointing results for two Phase II trials, it was ending its development of angiopoietin2 antibody nesvacumab as an addition to Eylea.

  November 27, 2017

   · 

  2 min read

   · 

  Mark Terry
• 

  Job Trends

  Merck Plots 950-Job R&D Hub in London

  The move is in part related to Brexit, the UK’s exit from the European Union.

  November 27, 2017

   · 

  2 min read

   · 

  Mark Terry
• 

  Job Trends

  Qiagen Plans to Create Up to 800 Jobs at New UK Campus Post Brexit

  Qiagen’s investment will be an expansion of its current operations in that northern England city.

  November 27, 2017

   · 

  2 min read

   · 

  Alex Keown
• 

  Deals

  Why Shire Should Spin Off Its Neuroscience Biz and Merge With This Maryland Pharma

  Kenneth Pittman, writing for Seeking Alpha, takes a look at why Shire is thinking of unloading its neuroscience division and suggesting an alternative.

  November 27, 2017

   · 

  3 min read

   · 

  Mark Terry
• 

  Drug Development

  Innate Tanked as Drug Combined With Bristol-Myers’ Opdivo Flopped in Study

  While lirilumab was shown to be well-tolerated, it did not demonstrate efficacy in treating that patient population.

  November 27, 2017

   · 

  2 min read

   · 

  Alex Keown
• 

  Biotech Bay

  Bay Area’s Medeor Therapeutics Bags $57M

  The financing will be used to push its Phase III clinical program of MDR-101 in living donor HLA-matched kidney transplant patients.

  November 27, 2017

   · 

  2 min read

   · 

  Mark Terry
• BioMidwest

  3 Top Diabetes Biotechs to Buy Into Right Now

  Diabetes is huge problem for Americans.

  November 27, 2017

   · 

  1 min read
• 

  Business

  Israel’s Protalix to Slash 20% of Workforce

  Share prices for Protalix are up more than 3 percent this morning after the company reported positive results from its Phase I/II open label extension trial of pegunigalsidase alfa, PRX-102, for the treatment of Fabry disease.

  November 27, 2017

   · 

  2 min read

   · 

  Alex Keown
• Business

  Lee’s Pharm Forms Second China Cancer Partnership With Beijing Shenogen

  In the latest joint effort, Lee’s Pharm will pair its PD-L1 candidate with icaritin.

  November 27, 2017

   · 

  1 min read